MCAS Diagnostic Criteria “Consensus-2" with Dr. Lawrence Afrin as part of the Mast Cell Matters series

In this episode, Dr. Lawrence Afrin discusses the shortcomings of the initial consensus statement on mast cell activation syndrome (MCAS), particularly the over-reliance on elevated tryptase levels for diagnosis. He argues for a broader approach to diagnosis, as many patients with MCAS do not exhibit elevated tryptase levels but still suffer from mast cell-related symptoms. Dr. Afrin and his colleagues have developed an alternative consensus, termed 'Consensus 2,' which considers a wider range of mast cell mediators in diagnosis, thus broadening the scope for diagnosing and treating MCAS. This approach aims to address the complexity and heterogeneity of MCAS, emphasizing that many patients can be correctly diagnosed and treated even when classic markers do not fit the typical patterns. The conversation touches on the necessity for medical professionals to adapt their understanding of MCAS to improve patient outcomes, as well as the need to educate clinicians worldwide on the diversity of presentations of MCAS.